Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for QuidelOrtho Corporation (QDEL:NASDAQ), powered by AI.
QuidelOrtho Corporation is currently trading at $16.50. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for QuidelOrtho Corporation on Alpha Lenz.
QuidelOrtho Corporation's P/E ratio is -1.0.
“QuidelOrtho Corporation trades at a P/E of -1.0 (undervalued) with modest ROE of -46.1%.”
Ask for details →QuidelOrtho Corporation is a leading manufacturer and provider of diagnostic testing solutions that serve the healthcare industry on a global scale. The company focuses on developing innovative diagnostic products designed to detect and diagnose a variety of medical conditions with increased accuracy and efficiency. QuidelOrtho's portfolio includes rapid diagnostic tests, traditional laboratory assays, and immunoassays that are used in clinical laboratories, hospitals, and primary care environments. The key feature of QuidelOrtho's offerings lies in its emphasis on providing reliable and timely diagnosis, which helps healthcare professionals in making informed decisions for patient care. Products from QuidelOrtho cover a broad spectrum of medical areas, including infectious diseases, cardiology, women’s health, and gastrointestinal conditions, significantly impacting public health outcomes. In the financial market, QuidelOrtho Corporation plays a crucial role in the healthcare sector, especially during times of heightened health crises. The company's commitment to advancing diagnostic technologies underscores its relevance amidst rising demand for rapid and accurate testing solutions in the medical field globally.
“QuidelOrtho Corporation trades at a P/E of -1.0 (undervalued) with modest ROE of -46.1%.”
Ask for details →QuidelOrtho Corporation (ticker: QDEL) is a company listed on NASDAQ in the Healthcare sector (Medical Devices). It has approximately 6,600 employees. Market cap is $1.1B.
The current price is $16.5 with a P/E ratio of -0.99x and P/B of 0.58x.
ROE is -46.15% and operating margin is 2.01%. Annual revenue is $2.7B.